HALOZYME THERAPEUTICS, INC. Cash and Restricted Cash
HALOZYME THERAPEUTICS, INC. (HALO) had Cash and Restricted Cash of $163.99 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $163.99M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $312.01M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $136.42M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $419.67M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $163.99M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $312.01M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $136.42M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $419.67M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $61.86M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $176.33M 10-Q · filed 2026-05-11 | |
| 2024-12-31 | $115.85M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $154.32M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $187.86M 10-Q · filed 2025-08-05 | |
| 2024-03-31 | $164.63M 10-Q · filed 2025-05-06 | |
| 2023-12-31 | $118.37M 10-K · filed 2026-02-17 | |
| 2023-09-30 | $274.23M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $221.16M 10-Q · filed 2024-08-06 | |
| 2023-03-31 | $96.88M 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $234.69M 10-K · filed 2026-02-17 | |
| 2022-09-30 | $147.66M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $91.43M 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $118.33M 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $119.22M 10-K · filed 2025-02-18 | |
| 2021-09-30 | $492.18M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $447.47M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $499.95M 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $148.20M 10-K · filed 2024-02-20 | |
| 2020-09-30 | $66.24M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $134.11M 10-Q · filed 2021-08-09 | |
| 2020-03-31 | $105.32M 10-Q · filed 2021-05-10 | |
| 2019-12-31 | $120.68M 10-K · filed 2023-02-21 | |
| 2019-09-30 | $59.70M 10-Q · filed 2020-11-02 | |
| 2019-06-30 | $67.54M 10-Q · filed 2020-08-10 | |
| 2019-03-31 | $61.09M 10-Q · filed 2020-05-11 | |
| 2018-12-31 | $58.44M 10-K · filed 2022-02-22 | |
| 2018-09-30 | $55.52M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $55.67M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $98.51M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $169.24M 10-K · filed 2021-02-23 | |
| 2017-09-30 | $164.90M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $115.25M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $115.25M 10-Q · filed 2018-08-07 | $45.69M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $67.26M 10-K · filed 2020-02-24 | |
| 2016-09-30 | $61.71M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $61.73M 10-Q · filed 2017-08-08 | |
| 2015-12-31 | $43.79M 10-K · filed 2019-02-21 | |
| 2014-12-31 | $61.89M 10-K · filed 2018-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |